Form 6-K Polyrizon Ltd. For: Apr 27

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of April 2026

 

Commission file number: 001-42375

 

Polyrizon Ltd.

(Translation of registrant’s name into English)

 

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒         Form 40-F ☐

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on April 27, 2026, titled “Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform.”

 

 

EXHIBIT INDEX

 

Exhibit No.
99.1		Press release titled: “Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Polyrizon Ltd.
Date: April 27, 2026	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES FILING OF EUROPEAN PATENT APPLICATION FOR ITS BREAKTHROUGH DRUG DELIVERY PLATFORM"

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• New Online Resource Hub Empowers Gallbladder Cancer Patients and Caregivers with Critical Guidance and Support
• PACSUN AND ANGEL CITY FOOTBALL CLUB SCORE THEIR FIRST CAPSULE COLLECTION
• IT By Design to Host Executive AI Training at Build IT LIVE 2026